MedTrace Logo

A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)

NCT00767793 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2015-10-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of INS117548 ophthalmic solution.

Conditions

Interventions

DRUG

Placebo

One drop in each eye every 12 hours for seven days

DRUG

INS117548

One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days

DRUG

INS117548

One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days

DRUG

INS117548

One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days

Sponsors & Collaborators

Principal Investigators

  • Reza Haque, MD, PhD · Medical Monitor, Inspire

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-05-31
Completion
2009-05-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00767793 on ClinicalTrials.gov